Skip to main content
Login
Contact
Subscribe
Search form
Search
The Sweetwater Reporter
Home
Forms
News
Sports
Classifieds
Obituaries
Entertainment
Local Guide
Special Sections
Talking About...
Photos
Videos
Games
Markets
Stocks
Funds
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
New York Composite
Gold
Crude Oil
Fate Therapeutics
(NQ:
FATE
)
14.03
USD
+0.67 (+5.01%)
Official Closing Price
/ Updated:
7:22 PM EDT, Sep 20, 2018
/
Add to My Watchlist
View:
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
Press Releases
Related Stories
Blogs
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Intraday
1 Week
1 Month
3 Month
1 Year
Compare to:
None
S&P 500
Nasdaq
NYSE
AMEX
Russell 2000
Basic Materials
Conglomerates
Consumer Goods
Financial
Healthcare
Industrial Goods
Services
Technology
Utilities
Volume
1,046,300
Open
13.56
Bid (Size)
13.91 (2)
Ask (Size)
14.19 (1)
Prev. Close
13.36
Today's Range
13.43 - 14.95
52wk Range
3.590 - 14.95
Shares Outstanding
52,858,446
Dividend Yield
N/A
Performance
YTD
+122.70%
+122.70%
1 Month
+23.72%
+23.72%
3 Month
+7.26%
+7.26%
6 Month
+28.01%
+28.01%
1 Year
+239.71%
+239.71%
Top News
More News
Fate Therapeutics Announces Pricing of Public Offering of Common Stock
Today 23:37 EDT
Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, today announced...
Read More
from
GlobeNewswire News Releases
Fate Therapeutics Announces Proposed Public Offering of Common Stock
Today 16:11 EDT
Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, today announced...
Read More
from
GlobeNewswire News Releases
More News
Read More
Fate Therapeutics Announces Strategic Collaboration with ONO Pharmaceutical to Develop Off-the-Shelf, iPSC-derived CAR-T Cell Cancer Immunotherapies
September 17, 2018
from
GlobeNewswire News Releases
Fate Therapeutics Enters into Exclusive License Agreement with Gladstone Institutes for CRISPR-based Cellular Reprogramming
September 13, 2018
from
GlobeNewswire News Releases
Research Report Identifies Kronos Worldwide, The Gap, Citigroup, Cadence Design, SPX FLOW, and Fate Therapeutics with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement
August 31, 2018
from
GlobeNewswire News Releases
Fate Therapeutics to Present at Upcoming Investor Conferences
August 29, 2018
from
GlobeNewswire News Releases
Fate Therapeutics to Present at the 2018 Wedbush PacGrow Healthcare Conference
August 07, 2018
from
GlobeNewswire News Releases
Fate Therapeutics Reports Second Quarter 2018 Financial Results and Highlights Operational Progress
August 06, 2018
from
GlobeNewswire News Releases
Fate Therapeutics to Webcast Conference Call Reporting Second Quarter 2018 Financial Results
July 30, 2018
from
GlobeNewswire News Releases
Recent Analysis Shows Synopsys, Rigel Pharmaceuticals, Fate Therapeutics, Philip Morris International, Sally Beauty, and Kimberly-Clark Market Influences — Renewed Outlook, Key Drivers of Growth
July 27, 2018
from
GlobeNewswire News Releases
SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Fate Therapeutics, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors
July 26, 2018
from
PR Newswire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Six Financial & Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
